Cover -- Half-title -- Title -- Copyright -- Contents -- Contributors -- Foreword -- Preface -- Acknowledgments -- Section 1 Basic science -- 1 Basic science -- The human hemopoietic system -- Hemopoietic growth factors -- The hemopoietic stem cell -- Hematopoietic stem cell differentiation -- The human marrow microenvironment -- Stem cell homing -- The cell cycle -- The human immune system -- Antigen presentation by the MHC -- T cell-B cell collaboration -- CD markers and currently recognized leukocyte surface antigens -- Adhesion molecules -- Cytokines and their function -- Chemokines -- Natural killer cells -- NK cell inhibition and activation -- Dendritic cells -- The mesenchymal stem cells -- Further Reading -- Section 2 Hematologic malignancies -- 2 Therapeutic decision making in BMT/SCT for acute myeloid leukemia -- Classification of acute myeloid leukemia -- Cytochemical and immunohistochemical stains used for the classification of acute leukemia -- Cytochemical, cytogenetic, and immune phenotype features of AML -- Other variants -- Acute undifferentiated leukemia -- Acute mixed lineage leukemia -- Prognostic factors -- Results with conventional therapy in adults -- Results with allogeneic and autologous transplant -- Indications for transplant -- Pretransplant workup -- Monitoring posttransplant -- Treatment algorithm for acute myeloid leukemia (AML) -- Induction -- Consolidation in remission -- Relapsed or refractory AML -- Further reading -- 3 Therapeutic decision making in BMT/SCT for acute lymphoblastic leukemia -- Classification of acute lymphoblastic leukemia -- FAB classification -- Immune phenotype classification -- Prognostic factors -- Results with conventional therapy in adults -- Results with allogeneic transplant -- CIBMTR data -- Indications for transplant -- HLA-identical family member transplant.

Autologous blood/marrow stem cell transplant -- HLA-identical unrelated donor transplant -- Special aspects of transplant in children -- Contraindications to transplant -- Pretransplant workup -- Monitoring posttransplant -- Further Reading -- 4 Therapeutic decision making in BMT/SCT for chronic myeloid leukemia and other myeloproliferative syndromes -- Classification of chronic myeloid leukemia -- Staging of CML -- Prognostic factors for outcome with conventional chemotherapy -- Definitions of hematologic, cytogenetic, and molecular responses -- Results with conventional therapy -- Results with allogeneic transplant -- CIBMTR-data -- Donor lymphocyte infusions for relapse of CML after allogeneic transplant -- Results with allogeneic transplant for CML in children -- Results with autologous transplant for CML -- Results with reduced-intensity allogeneic transplant for CML -- Results with allogeneic transplant for myeloproliferative syndromes other than CML -- Indications for allogeneic transplant in CML (Recommendations of the European Leukemia NET) -- Contraindications -- Pretransplant workup -- Monitoring posttransplant -- Further Reading -- 5 Therapeutic decision making in BMT/SCT for chronic lymphatic leukemia -- Disease staging -- Immune phenotype and cytogenetic abnormalities -- Cytogenetic findings -- Prognostic factors -- Results with conventional therapy -- Purine analogues -- Results with fludarabine and rituximab -- Results with pentostatin and cyclophosphamide -- Results with alemtuzumab -- Bendamustine -- Results with allogeneic transplant -- Autologous compared with allogeneic stem cell transplantation for poor-risk CLL -- Nonmyeloablative transplantation for advanced chronic lymphocytic leukemia -- Predictors of disease-free survival after a nonmyeloablative allogeneic stem cell transplant for advanced chronic lymphocytic leukemia.

Results with autologous transplant -- Special problems in transplantation for CLL -- Indications for transplant -- HLA-identical sibling transplant -- Autologous blood/marrow stem cell transplant -- Contraindications to transplant -- Pretransplant workup -- Monitoring posttransplant -- Further reading -- 6 Therapeutic decision making in BMT/SCT for myelodysplasia -- Disease staging and classification -- Cytogenetic abnormalities -- Characteristics of MDS and acute myeloid leukemia secondary to prior chemotherapy -- Options for conventional treatment for MDS -- Results with conventional therapy and new agents -- Results with autologous transplant -- Results with allogeneic transplant -- Indications for transplant -- HLA-identical family member transplant -- HLA-matched (for 9 of 10 antigens) family member or matched unrelated transplant -- Autologous blood/marrow stem cell transplant -- Contraindications to transplant -- Pretransplant workup -- Monitoring posttransplant -- Further reading -- 7 Therapeutic decision making in BMT/SCT for non-Hodgkin lymphoma -- Disease classification -- Disease staging -- Immune phenotype of lymphoid neoplasms, cytogenetic,and molecular abnormalities -- Prognostic factors for outcome with conventional therapy -- CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma -- Probability of survival after autotransplants for follicular lymphoma -- Treatment recommendations for aggressive lymphoma (excluding Burkitt and lymphoblastic lymphoma) -- Diffuse large B-cell lymphoma -- Mantle cell lymphoma -- Primary mediastinal B-cell lymphoma -- T-cell lymphoma -- 8 Therapeutic decision making in BMT/SCT for Hodgkin lymphoma -- Disease classification -- Disease staging -- Prognostic factors for outcome with conventional therapy -- Risk factors for early-stage Hodgkin lymphoma.

Risk factors for advanced Hodgkin lymphoma -- Results with conventional therapy in adult patients -- Results with autologous transplant -- High-dose therapy and autologous hematopoietic stem cell transplantation for recurrent or refractory pediatric Hodgkin lymphoma (41 patients, Stanford University Medical Center) -- Results with myeloablative allogeneic transplant -- Results with nonmyeloablative allogeneic transplant -- Indications for autologous transplant -- Recommendations for salvage chemotherapy -- Contraindications to autologous transplant -- Indications for allogeneic transplant -- Monitoring posttransplant -- Further reading -- 9 Therapeutic decision making in hematopoietic stem cell transplantation for multiple myeloma -- Diagnosis -- Adverse prognostic factors -- Standard-dose therapy in the up-front treatment of multiple myeloma -- CIBMTR data for multiple myeloma -- Conclusions from recent studies -- Indications for transplantation -- Contraindications to Transplantation -- Pretransplant workup -- Monitoring posttransplant -- Further reading -- 10 Therapeutic decision making in BMT/SCT for amyloidosis -- Definition -- Disease classification -- Results of conventional therapy -- Results of autologous transplantation -- Indications for transplantation -- Contraindications to transplantation -- Follow-up after transplantation -- Further reading -- Section 3 Solid tumors -- 11 Therapeutic decision making in stem cell transplantation for breast cancer -- Further reading -- 12 Therapeutic decision making in BMT/SCT for nonseminomatous germ cell tumor of testis (NSGCT) -- Introduction -- Disease classification -- Disease staging and rationale for high-dose therapy -- Prognostic factors for outcome with conventional therapy -- Results with autologous transplant -- Risk factors before autologous transplantation.

Tandem versus single autologous transplantation -- Possible indications for autologous transplant -- Pretransplant workup -- Monitoring posttransplant -- Further reading -- 13 Therapeutic decision making in BMT/SCT for renal cell cancer -- Introduction: Scientific rationale -- Results of conventional treatment -- Results of allogeneic transplantation -- Mechanisms accounting for graft-versus-RCC responses after transplantation -- Enhancing graft-versus-RCC: What is next? -- Future directions -- Further Reading -- 14 Therapeutic decision making in BMT/SCT for soft tissue sarcomas -- Disease classification -- Results with high-dose therapy followed by autologous stem cell transplant -- Neuroblastoma -- Indications for autologous transplantation in neuroblastoma -- Ewing sarcoma and other soft tissue sarcomas -- Further reading -- Section 4 Nonmalignant disorders -- 15 Therapeutic decision making in BMT/SCT for severe aplastic anemia -- Etiology -- Disease staging -- Results with conventional therapy -- Results with allogeneic transplant -- Indications for allogeneic transplant -- Pretransplant workup -- Monitoring posttransplant -- Further reading -- 16 Therapeutic decision making in BMT/SCT for congenital immunodeficiencies -- Introduction -- Results of BMT/SCT for SCID -- Results of BMT/SCT for non-SCID immunodeficiencies -- Reduced-intensity conditioning for congenital immunodeficiencies -- Indications for allogeneic transplant -- Contraindications to allogeneic transplant -- Further reading -- 17 Therapeutic decision making in BMT/SCT for hemoglobinopathies -- B-Thalassemia syndromes -- Complications of sickle cell disease -- Results with conventional therapy for thalassemia -- Results with conventional therapy for sickle cell disease -- Results with allogeneic transplant for thalassemia major.

Results with allogeneic transplant for sickle cell disease.